Ketamine Administration by Special Operations Medical Personnel During Training Mishaps

Fisher, Andrew D; Schwartz, Darin S; Petersen, Christopher; Meyer, Stephen E; Thielemann, Joseph N; Redman, Theodore T.; Rush, Stephen

doi:10.55460/ergu-pez2

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ketamine has a favorable safety profile 7,8 and is currently used on the battlefield as a first-line intervention for moderate to severe pain when the casualty is in hemorrhagic shock, in respiratory distress, or at significant risk of developing either condition 9 . Intramuscular or intranasal routes of administration demonstrate comparable efficacy with that of intravenous administration 10,11 . Ketamine is currently approved by the Food and Drug Administration (FDA) as an anesthetic agent, so the use for pain control is considered off-label.…”

Section: Resultsmentioning

confidence: 99%

“…9 Intramuscular or intranasal routes of administration demonstrate comparable efficacy with that of intravenous administration. 10,11 Ketamine is currently approved by the Food and Drug Administration (FDA) as an anesthetic agent, so the use for pain control is considered off-label. Consequently, formulation and packaging of ketamine for pain control cannot be developed at present.…”

Section: Statement #2: Ketamine Is An Effective and Safe Analgesic Fo...mentioning

confidence: 99%

See 1 more Smart Citation

Battlefield pain summit 2022: Expert consensus statements

Stark¹,

Davidson²,

Cannon³

et al. 2022

J Trauma Acute Care Surg

View full text Add to dashboard Cite

BACKGROUND: Battlefield pain occurs in combat casualties who experience multiple severe injuries. The nature of battlefield scenarios requires a distinct approach to battlefield pain research. A battlefield pain summit was thus convened to identify shortcomings in the current understanding of battlefield pain management, review the current state of battlefield pain research, and shape the direction of future research. METHODS:On January 10 to 11, 2022, a hybrid in-person and virtual meeting hosted by the US Army Institute of Surgical Research defined research priorities for the Combat Casualty Care Research Program's Battlefield Pain research portfolio. Summit participants identified the following key focus areas under the umbrella of battlefield pain research: battlefield injury patterns; use of ketamine and nonopioid analgesics; analgesic delivery systems; the impact of analgesia on performance, cognition, and survival; training methods; battlefield regional anesthesia; and research models. Preliminary statements presented during the summit were refined and rank ordered through a Delphi process. RESULTS:Consensus was achieved on 7 statements addressing ideal analgesic properties, delivery systems, operational performance concerns, and pain training. Ketamine was identified as safe and effective for battlefield use, and further research into nonopioid analgesics represented a high priority. CONCLUSION: The 7 consensus statements that emerged from this battlefield pain summit serve as a template to define the near-term research priorities for military-specific battlefield pain research.

show abstract

Section: Resultsmentioning

confidence: 99%